Need for immunization against viral hepatitis. Persons with potential health hazards related to communicable diseases
Conditions
Interventions
Intervention 1: Placebo: administered orally from one week prior to every hepatitis-B vaccination dose to one week after. Intervention 2: Intervention: levamisole administered orally from one week pri
Treatment - Drugs
Placebo: administered orally from one week prior to every hepatitis-B vaccination dose to one week after.
Intervention: levamisole administered orally from one week prior to every hepatitis-B vaccination dose to one week after.
Sponsors
Mashad University of Medical Sciences
Eligibility
Sex/Gender
All
Age
16 Years to 70 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: 16 years old and older without a history of a chronic disease or previous hepatitis B vaccination. Exclusion criteria: current smoking and/or addiction to any form of drug; body mass index above 30 kg/m2; previous history of hepatitis B vaccination or infection; positive testing for HBs Ag or HBs Ab; any current chronic and/or acute disease.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Response rate to the hepatitis B vaccine when levamisole is co-administered. Timepoint: HBs Ab levels are measured one month after the final dose of the vaccine. Method of measurement: Laboratory. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMousalreza Hosseini
Mashad University Of Medical Sciences
Outcome results
None listed